Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients

( views:76, downloads:0 )
SUN Cong-cong(Department of Neurology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China)
LUO Fei-fei(Department of Neurology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China)
WEI Lei(Department of Neurology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China)
LEI Mi(Department of Neurology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China)
LI Guo-fei(Department of Neurology, Huaihe Hospital of Henan University,Kaifeng, Henan 47500, China)
LIU Zhuo-lin(Department of Neurology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China)
LE Wei-dong(Department of Neurology, Baylor College of Medicine, 6501Fannin Street, Houston, TX, 77030, USA;The Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China)
XU Ping-yi(Department of Neurology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China)
Journal Title:
Chinese Medical Journal
Volume 125, Issue 04, 2012
Key Word:
uric acid;Parkinson's disease;disease progression

Abstract: Background Uric acid (UA) is suspected to play a neuro-protective role in Parkinson's disease (PD).This study aimed to evaluate whether the serum UA level was associated with the disease progression of PD in a relatively large population of Chinese patients.Methods Serum UA levels were measured from 411 Chinese PD patients and 396 age-matched controls; following the uric acid colorimetric method,the serum creatinine (Scr) levels were also measured to reduce the bias caused by possible differences in renal excretion function.The disease progression was scored by Hoehn and Yahr (H&Y) scales and disease durations; PD group was divided into 3 subgroups according to H&Y scales.Independent-samples ttest was performed to analyze the differences between PD group and control group.Multiple analysis of covariance was performed to analyze the differences between PD subgroups.Spearman rank-correlation was performed to evaluate the associations between serum UA or Scr level and disease progression.Results PD patients were found to have significantly lower levels of serum UA than controls ((243.38±78.91) vs.(282.97±90.80) pmol/L,P<0.01).As the disease progression,the serum UA levels were gradually reduced.There was a significantly inverse correlation of UA levels with H&Y scales (Rs=-0.429,P <0.01) and disease duration (Rs=-0.284,P <0.01) in PD patients of both females and males.No significant difference of the Scr level between PD patients and controls was found ((70.01±14.70) vs.(69.84±16.46) μmol/L),and the Scr level was not involved in disease progression.Conclusion Lower serum UA levels may possess a higher risk of PD,which may be a potential useful biomarker to indicate the progression of PD.

  • 1.Jankovic J.Parkinson's disease therapy:treatment of early and late disease.Chin Med J 2001; 114:227-234.
  • 2.Ren JP,Zhao YW,Sun XJ.Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL/6 mice.Chin Med J 2009; 122:2366-2371.
  • 3.Davies K J,Sevanian A,Muakkassah-Kelly SF,Hochstein P.Uric acid-iron ion complexes.A new aspect of the antioxidant functions of uric acid.Biochem J 1986; 235:747-754.
  • 4.Duan W,Ladenheim B,Cutler RG,Kruman Ⅱ,Cadet JL,Mattson MP.Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.J Neurochem 2002; 80:101-110.
  • 5.Facheris MF,Hicks AA,Minelli C,Hagenah JM,Kostic V,Campbell S,et al.Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease.J Mol Neurosci 2011; 43:246-250.
  • 6.Church WH,Ward VL.Uric acid is reduced in the substantia nigra in Parkinson's disease:effect on dopamine oxidation.Brain Res Bull 1994; 33:419-425.
  • 7.Davis JW,Grandinetti A,Waslien CI,Ross GW,White LR,Morens DM.Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease.Am J Epidemiol 1996;144:480-484.
  • 8.Ascherio A,LeWitt PA,Xu K,Eberly S,Watts A,Matson WR,et al.Urate as a predictor of the rate of clinical decline in Parkinson disease.Arch Neurol 2009; 66:1460-1468.
  • 9.Gao X,Chen H,Choi HK,Curhan G,Schwarzschild MA,Ascherio A.Diet,urate,and Parkinson's disease risk in men.Am J Epidemiol 2008; 167:831-838.
  • Lau LM,Koudstaal PJ,Hofman A,Breteler MM.Serum uric acid levels and the risk of Parkinson disease.Ann Neurol 2005; 58:797-800.
  • 11.Schiess M,Oh I.Serum uric acid and clinical progression in Parkinson disease:potential biomarker for nigrostriatal failure.Arch Neurol 2008; 65:698-699.
  • 12.Schwarzschild MA,Schwid SR,Marek K,Watts A,Lang AE,Oakes D,et al.Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.Arch Neurol 2008; 65:716-723.
  • 13.Andreadou E,Nikolaou C,Gournaras F,Rentzos M,Boufidou F,Tsoutsou A,et al.Serum uric acid levels in patients with Parkinson's disease:their relationship to treatment and disease duration.Clin Neurol Neurosurg 2009;111:724-728.
  • 14.Winquist A,Steenland K,Shankar A.Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey.Mov Disord 2010; 25:932-936.
  • 15.Meara J,Bhowmick BK,Hobson P.Accuracy of diagnosis in patients with presumed Parkinson's disease.Age Ageing 1999; 28:99-102.
  • 16.Hughes AJ,Daniel SE,Kilford L,Lees AJ.Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry 1992; 55:181-184.
  • 17.Chen H,Mosley TH,Alonso A,Huang X.Plasma urate and Parkinson's disease in the Atherosclerosis risk in Communities (ARIC) study.Am J Epidemiol 2009; 169:1064-1069.
  • 18.Annanmaki T,Muuronen A,Murros K.Low plasma uric acid level in Parkinson's disease.Mov Disord 2007; 22:1133-1137.
  • 19.Ames BN,Cathcart R,Schwiers E,Hochstein P.Uric acid provides an antioxidant defense in humans against oxidantand radical-caused aging and cancer:a hypothesis.Proc Natl Acad Sci U S A 1981; 78:6858-6862.
  • 20.Whiteman M,Ketsawatsakul U,Halliwell B.A reassessment of the peroxynitrite scavenging activity of uric acid.Ann N Y Acad Sci 2002; 962:242-259.
  • 21.Shadrina MI,Slominsky PA,Limborska SA.Molecular mechanisms of pathogenesis of Parkinson's disease.Int Rev Cell Mol Biol 2010; 281:229-266.
  • 22.Bierer DW, Quebbemann AJ.Effect of 1-Dopa on renalhandling of uric acid.J Pharmacol Exp Ther 1982; 223:55-59.
  • 23.Pinheiro-Carrera M,Tomaz C,Huston JP,Dai H,Carey RJ.1-Dopa induced increases in brain uric acid in an animal model of Parkinson's disease:a relationship to behavioral activation.Life Sci 1994; 55:991-997.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615